Royalty Pharma Nears Biopharma Record Take With $2.18bn IPO

 
• By Joseph Haas

Company specializing in trading upfront cash for downstream earnings makes its public debut with largest IPO of 2020, and the second largest ever in biopharma.

FUNDING word written on wood block
With the largest IPO of 2020, Royalty Pharma sees plenty of investment opportunities

More from Financing

More from Business